MRNA Announces management changes
Summary
Moderna, Inc. appointed Michael McDonnell to its Board of Directors, effective July 8, 2026, as announced in a press release furnished as Exhibit 99.1. Mr. McDonnell will serve as a Class II director until the 2029 annual meeting and was also appointed to the Audit Committee. Simultaneously, David Rubenstein ceased serving on the Audit Committee and was appointed to the Nominating and Corporate Governance Committee. Mr. McDonnell brings over 35 years of financial leadership, including his recent role as Chief Financial Officer of Biogen Inc.
Why It Matters
The appointment of Michael McDonnell, a director with over 35 years of financial leadership and public company experience, including as a former CFO of a major life sciences company, strengthens Moderna's Board and its Audit Committee. This enhances corporate governance and financial oversight, which is a positive signal for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025.”
— From Item 5.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Wednesday, July 8, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral